Navigation Links
CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
Date:11/26/2007

HREF="http://www.curagen.com" target="_new">http://www.curagen.com or by emailing info@curagen.com.

About Belinostat

Belinostat is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine, idarubicin and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti- cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti- cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About CuraGen

CuraGen Corporation (Nasdaq: '/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...  Together with its parent partners and the Community ... initiative of Morris County Prevention is Key (MCPIK), the ... community effort to address the heroin/opiate crisis in ... Volunteer Parent Coaches from the Partnership, ... Denise Mariano , National Council on Alcoholism and Drug ...
(Date:4/27/2015)... 2015 PAML announced today that the ... Axela, Inc. to develop multiplex assays focused on ... of the nation,s leading medical reference laboratories, and ... analysis for clinical diagnostics. Axela,s ... assay development serves as the foundation for novel ...
(Date:4/27/2015)... Calif. , April 27, 2015  Eiger BioPharmaceuticals, ... Phase 2 data of lonafarnib in patients with chronic ... the LOWR HDV program, enrolled at Ankara University Medical ... where HDV is endemic. LOWR HDV ... parallel dose comparison study which randomized subjects to receive ...
Breaking Medicine Technology:Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 3PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
... (NYSE: CFN ), a leading, global medical ... point-of-care verification suite of products across 153 U.S. Department ... centers. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... users of barcode medication administration technology and this agreement ...
... NEW YORK, Dec. 6, 2010 Keryx Biopharmaceuticals, ... data presented for the first time at the ... Hematology showing promising clinical activity, safety and tolerability ... leukemia (CLL) and Hodgkin,s lymphoma (HL).  KRX-0401 (perifosine) ...
Cached Medicine Technology:CareFusion to Provide Pyxis® Point-of-Care Products to Veterans Affairs Hospitals Nationwide 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable assisted living community, ... from 10:30 a.m. to noon on May 8. , ... St. in Chicago, serves low-income older adults, including those ... independence. , “Mothers, grandmothers, godmothers and mothers-to-be are invited ... Director of Marketing Elizabeth Clippard. , The menu will ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
(Date:4/27/2015)... How to Implement UDI:, Lessons from Early ... – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI , With ... restraint, there’s plenty of time to get ready for ... deadlines are coming fast for all devicemakers and soon ... even if it seems there’s no rush. It's already ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... mistakenly thought they were taking growth hormone, researchers say ... think they are taking a performance-enhancing drug, their performance ... really take the drug. , So concludes a study ... hormone supplements while the other half took a placebo. ...
... US primary care physicians,Novartis earns the highest sales ... Sanofi-Aventis, according to new,research from TNS Healthcare. Novartis ... consistent ability to build strong physician relationships.,Though Pfizer ... has,greater variability in Europe, while Merck,s European performance ...
... Kimberly-Clark Professional is,donating thousands of health and ... clean up from the extensive damage caused by ... hit very hard by these storms and the,flooding ... Professional, North America. "At Kimberly-Clark,Professional, our mission is ...
... ,Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global ... from a,randomized, long-term safety and tolerability study (study ... primary endpoints,of this study were to assess the ... over 12 months. Data were published in the,July ...
... in cells more readily than a commonly used colorectal ... colorectal tumors, but with fewer side effects, MIT researchers ... a potent anticancer agent, but the newly investigated compound, ... sparing other body tissues from damage. , "This compound, ...
... trauma is an extremely rare condition. There is no ... abdominal trauma. Nonsurgical intervention, especially endoscopic treatment has recently ... case, led by Dr. TH Kim and his colleagues ... 14, 2008 in the World Journal of Gastroenterology. , ...
Cached Medicine News:Health News:Sports Doping's Effect May Be in the Mind 2Health News:Sports Doping's Effect May Be in the Mind 3Health News:Sports Doping's Effect May Be in the Mind 4Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 2Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 3Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 5Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 6Health News:MIT researchers see alternative to common colorectal cancer drug 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
500L...
Medicine Products: